TINN2 is a European research network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Programme of the 7 th Framework Programme.

News & Events


TINN European Survey on the Use of Antibiotics in NICUs

The survey results are now available and the published article has been published.

Please click here to consult it.


MANY THANKS to all the Neonatal Intensive Care Units that dedicated their time to partipate in the TINN2 survey.


Consortium final meeting on 8th October 2015, in Paris, France

The official event of the TINN2 FP7 European Research Project was organised by Inserm-Transfert on 8th October 2015 in Paris (France).

This meeting gathered together all TINN2 partners for presenting and discussing the latest progresses within TINN2 activities, a project on preclinical studies and paediatric investigation plans for children, under the coordination of the French National Institute of Health and Medical Research (Inserm).

European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom 31st to 4th April 2012


TINN2 Project was presented on Poster at the ECCMID congress in London, United Kingdom.

Brochure PDF :


The TINN2 strategy is organised around 6 complementary research activities or “work packages” (WP) focusing on:

gelule First of all, reviewing all available data on azithromycin, identifying and listing formulations/presentations of azithromycin used in neonates in Europe and finding the appropriate formulations/presentations of azithromycin for use in neonates.

gelule Developing in silico models of azithromycin effects based on all available knowledge and preparing a pilot study of azithromycin PharmacoKinetics (PK) designed to obtain high quality data on the pharmacokinetics, efficacy and tolerability of azithromycin, as well as a registry for long term follow-up of the babies. The information obtained will help in preparing and validating the components of a PIP (Paediatric Investigation Plan) for azithromycin in neonates to be submitted to EMA. We will ensure that the safety of the newborn infant (both in the short-term and long-term) is prioritised within the clinical trial design.

gelule Coordinating the preparation of the TINN2 EU-trial. We will make sure that the trial will be conducted in high quality clinical centres in Europe by appropriately trained investigators, performed through effective collaboration and ensure high ethical standards. All this with the objective of providing the information required for adequate drug use in neonates.

gelule Implementing the azithromycin PK and pivotal trials as described in the PIP.

gelule Monitoring all ethical aspects of the trials and organising short- and long-term safety monitoring via our independent safety monitoring boards in order to identify potential adverse drug reactions.

gelule Reporting of the results of the trial to EMA in order to obtain a PUMA and to the medical doctors and scientists in order to disseminate and properly exploit the information generated by TINN2.

One work package will guarantee the general coordination of the activities and the smooth communication between the partners of the TINN2 consortium, as well as the dissemination of the results generated by our activities outside the network so as to provide maximum benefit to the research community and the patients. Furthermore, our external advisory boards composed of independent experts will periodically review scientific results and progress of the clinically oriented activities as well as provide support for any ethical and safety issues.